Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHD
MCID: LPP008
MIFTS: 62

Lipoprotein Quantitative Trait Locus (CHD)

Categories: Cardiovascular diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lipoprotein Quantitative Trait Locus

About this section

MalaCards integrated aliases for Lipoprotein Quantitative Trait Locus:

Name: Lipoprotein Quantitative Trait Locus 56 37
Coronary Artery Disease 56 12 43 15
Coronary Artery Disease, Susceptibility to 56 29 6
Coronary Artery Anomaly 12 15
Myocardial Ischemia 43 17
Coronary Disease 12 43
Congenital Anomaly of Coronary Artery 12
Coronary Artery Anomaly, Congenital 12
Coronary Artery Abnormality 12
Lpa Deficiency, Congenital 56
Coronary Arteriosclerosis 12
Coronary Heart Disease 12
Coronary Syndrome 15
Chd 12

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11843 DOID:3393
OMIM 56 618807
UMLS 71 C0010054 C0010068 C0151744 more
Sources

Summaries for Lipoprotein Quantitative Trait Locus

About this section
OMIM : 56 Lipoprotein(a) is a macromolecular complex in human plasma which represents a quantitative genetic trait with a heritability of 0.7 or higher. Lipoprotein(a) is composed of an LDL-like particle in which apoB (107730) is covalently bound by a single disulfide bond to apolipoprotein(a). Apo(a) has been demonstrated to be the main determinant of the quantitative Lp(a) trait. Variation in the number of plasminogen (PLG)-like kringle (K) IV type 2 tandem repeats in the apo(a) gene is inversely correlated to Lp(a) plasma levels in all populations studied. Several polymorphisms in the Lp(a) gene have been found to affect the apo(a) concentration level (summary by Ogorelkova et al., 1999). (618807)

MalaCards based summary : Lipoprotein Quantitative Trait Locus, also known as coronary artery disease, is related to coronary heart disease 1 and angina pectoris. An important gene associated with Lipoprotein Quantitative Trait Locus is LPA (Lipoprotein(A)), and among its related pathways/superpathways are Folate Metabolism and cGMP-PKG signaling pathway. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Lipoprotein Quantitative Trait Locus

About this section

Diseases related to Lipoprotein Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1395)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 35.8 PON1 NPPB NOS3 MIR145 LPA EDN1
2 angina pectoris 33.8 TNNI3 NPPB NOS3 MB LPA KNG1
3 hypercholesterolemia, familial, 1 33.8 NOS3 LPA CRP COG2 APOB ACE
4 hyperlipidemia, familial combined, 3 33.7 PON1 COG2 APOB
5 familial hypercholesterolemia 33.6 PON1 NOS3 LPA CRP COG2 APOB
6 cardiac arrest 33.5 TNNT2 NPPB KNG1 ALB ACE
7 heart disease 33.5 TNNT2 TNNI3 PON1 NPPB NOS3 MIR223
8 lipid metabolism disorder 32.7 PON1 LPA IRS1 CRP COG2 APOB
9 intermediate coronary syndrome 32.6 TNNT2 TNNI3 PLG MIR145 MB LPA
10 ischemia 32.6 PON1 NPPB NOS3 MB KNG1 IL1RN
11 atherosclerosis susceptibility 32.6 PON1 NOS3 LPA EDN1 CRP COG2
12 coronary stenosis 32.5 TNNI3 PON1 NPPB CRP APOB ALB
13 vascular disease 32.3 PON1 PLG NPPB NOS3 MIR145 LPA
14 cerebrovascular disease 32.3 PON1 NPPB LPA CRP APOB ACE
15 diabetes mellitus, noninsulin-dependent 32.2 PON1 PLG NOS3 MB LPA IRS1
16 glucose intolerance 32.2 IRS1 CRP APOB ALB ACE
17 congestive heart failure 32.2 TNNT2 TNNI3 NPPB NOS3 KNG1 EDN1
18 peripheral vascular disease 32.2 NOS3 LPA KNG1 CRP COG2 APOB
19 homocysteinemia 32.1 PON1 NOS3 LPA CRP ALB
20 arteriosclerosis 32.1 PON1 NOS3 LPA EDN1 CRP COG2
21 myocardial infarction 32.1 TNNT2 TNNI3 PON1 PLG NPPB NOS3
22 kidney disease 32.0 PON1 NPPB NOS3 LPA EDN1 CRP
23 acute myocardial infarction 32.0 TNNT2 TNNI3 PLG NPPB MIR223 MIR150
24 chronic kidney disease 32.0 TNNT2 TNNI3 PON1 NPPB NOS3 MIR223
25 body mass index quantitative trait locus 11 32.0 PON1 NOS3 MIR223 LPA KNG1 IRS1
26 diabetes mellitus 32.0 PON1 NPPB NOS3 MIR223 MIR145 LPA
27 sleep apnea 32.0 NPPB NOS3 EDN1 CRP APOB ALB
28 fatty liver disease 31.9 IRS1 CRP APOB ALB
29 hyperglycemia 31.9 NOS3 IRS1 APOB ALB
30 hypothyroidism 31.9 PON1 LPA CRP COG2 APOB ALB
31 impotence 31.9 NOS3 KNG1 EDN1 ALB ACE
32 peripheral artery disease 31.9 NPPB NOS3 EDN1 CRP APOB ACE
33 pulmonary disease, chronic obstructive 31.9 NPPB MIR223 MB CRP ALB ACE
34 coronary thrombosis 31.9 PLG CRP ACE
35 stroke, ischemic 31.9 PON1 PLG NPPB NOS3 MB LPA
36 atrial fibrillation 31.8 TNNT2 TNNI3 NPPB NOS3 MIR150 CRP
37 mitral valve insufficiency 31.8 TNNT2 TNNI3 NPPB CRP ALB ACE
38 end stage renal disease 31.8 PON1 NOS3 IL1RN CRP ALB ACE
39 hypertension, essential 31.8 TNNT2 TNNI3 PON1 PLG NPPB NOS3
40 atrial standstill 1 31.7 TNNT2 TNNI3 NPPB ACE
41 microvascular complications of diabetes 5 31.7 PON1 PLG NOS3 ALB ACE
42 hyperuricemia 31.7 CRP APOB ALB
43 carotid stenosis 31.7 NOS3 LPA CRP ACE
44 cardiovascular system disease 31.7 PON1 PLG NPPB NOS3 MIR223 MIR150
45 familial hyperlipidemia 31.7 PON1 LPA CRP COG2 APOB ACE
46 intermittent claudication 31.6 TNNT2 CRP ALB ACE
47 osteoporosis 31.6 NPPB NOS3 LPA IRS1 IL1RN EDN1
48 dilated cardiomyopathy 31.6 TNNT2 TNNI3 NPPB NOS3 MB KNG1
49 anterolateral myocardial infarction 31.6 NPPB ACE
50 heart valve disease 31.6 TNNI3 NPPB MIR150 LPA CRP ALB

Graphical network of the top 20 diseases related to Lipoprotein Quantitative Trait Locus:



Diseases related to Lipoprotein Quantitative Trait Locus
Sources

Symptoms & Phenotypes for Lipoprotein Quantitative Trait Locus

About this section

Clinical features from OMIM:

618807

MGI Mouse Phenotypes related to Lipoprotein Quantitative Trait Locus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ACE ALB APOB CRP EDN1 IL1RN
2 homeostasis/metabolism MP:0005376 9.8 ACE ALB APOB COG2 CRP EDN1
3 muscle MP:0005369 9.23 ALB APOB EDN1 IRS1 MB NOS3
Sources

Drugs & Therapeutics for Lipoprotein Quantitative Trait Locus

About this section

Drugs for Lipoprotein Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 930)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
2
Polyestradiol phosphate Approved Phase 4 28014-46-2
3
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
4
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
5
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
6
Zolpidem Approved Phase 4 82626-48-0 5732
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
8
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
14
Gliclazide Approved Phase 4 21187-98-4 3475
15
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
16
Pravastatin Approved Phase 4 81093-37-0 54687
17
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
18
Probucol Approved, Investigational Phase 4 23288-49-5 4912
19
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
20
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
21
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
22
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
23
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
24
Digoxin Approved Phase 4 20830-75-5 30322 2724385
25
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
26 Nutmeg Approved Phase 4
27
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
28
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
29
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
30
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
Famotidine Approved Phase 4 76824-35-6 3325
34
Eplerenone Approved Phase 4 107724-20-9 150310 443872
35
Sodium citrate Approved, Investigational Phase 4 68-04-2
36
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
37
Etomidate Approved Phase 4 33125-97-2 36339 667484
38
Glyburide Approved Phase 4 10238-21-8 3488
39
Linagliptin Approved Phase 4 668270-12-0 10096344
40
Propranolol Approved, Investigational Phase 4 525-66-6 4946
41
Trandolapril Approved Phase 4 87679-37-6 5484727
42
Cosyntropin Approved Phase 4 16960-16-0 16129617
43
Fondaparinux Approved, Investigational Phase 4 104993-28-4
44
Citalopram Approved Phase 4 59729-33-8 2771
45
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
46
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
47
Streptokinase Approved, Investigational Phase 4 9002-01-1
48
Ibuprofen Approved Phase 4 15687-27-1 3672
49
Adalimumab Approved Phase 4 331731-18-1 16219006
50
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 8022)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
4 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
5 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
6 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
7 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
8 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
9 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
10 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
11 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
12 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
13 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
14 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
15 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
16 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
17 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
18 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
19 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
20 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
21 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
22 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
23 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
24 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
25 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
26 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
27 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
28 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
29 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
30 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
31 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
32 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
33 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
34 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
35 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
36 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
37 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
38 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
39 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
40 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
41 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
42 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
43 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
44 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
45 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
46 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
47 Effect of Statins on the Progression of the Intima-media Thickness of the Radial Artery After Radial Angioplasty Unknown status NCT00952770 Phase 4
48 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography Unknown status NCT01024179 Phase 4
49 Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V Unknown status NCT00714545 Phase 4
50 The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery Unknown status NCT01623193 Phase 4

Search NIH Clinical Center for Lipoprotein Quantitative Trait Locus

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lipoprotein Quantitative Trait Locus cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lipoprotein Quantitative Trait Locus:
CD34+ stem cells for treatment of congestive heart failure
Embryonic/Adult Cultured Cells Related to Lipoprotein Quantitative Trait Locus:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120

Cochrane evidence based reviews: coronary artery disease

Sources

Genetic Tests for Lipoprotein Quantitative Trait Locus

About this section

Genetic tests related to Lipoprotein Quantitative Trait Locus:

# Genetic test Affiliating Genes
1 Coronary Artery Disease, Susceptibility to 29
Sources

Anatomical Context for Lipoprotein Quantitative Trait Locus

About this section

MalaCards organs/tissues related to Lipoprotein Quantitative Trait Locus:

40
Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung
Sources

Publications for Lipoprotein Quantitative Trait Locus

About this section

Articles related to Lipoprotein Quantitative Trait Locus:

(show top 50) (show all 30665)
# Title Authors PMID Year
1
Coronary artery disease and a functional polymorphism of hTERT. 6 61
16890917 2006
2
A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. 61 6
10591678 1999
3
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. 6 61
8770857 1996
4
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. 6 61
8675673 1995
5
Paraoxonase-1 is a major determinant of clopidogrel efficacy. 6
21170047 2011
6
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. 56
20032323 2009
7
Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. 56
18560444 2008
8
A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). 56
15523644 2004
9
Paraoxonase 1 polymorphisms and survival. 6
15241482 2004
10
Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. 6
15240653 2004
11
G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. 6
14707024 2004
12
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. 6
14671192 2003
13
Lp(a) lipoprotein, vascular disease, and mortality in the elderly. 56
14645638 2003
14
The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. 6
12843189 2003
15
Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. 6
12082503 2002
16
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 6
11918623 2002
17
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. 6
11888590 2002
18
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 6
11889198 2002
19
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 6
11788650 2002
20
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. 6
11810302 2002
21
Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. 56
11698280 2001
22
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 6
11335891 2001
23
Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. 56
11285247 2001
24
The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. 6
11238489 2001
25
The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. 6
10843189 2000
26
Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians. 56
10484779 1999
27
The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. 6
10430617 1999
28
Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. 6
10084586 1999
29
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 6
9661650 1998
30
Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. 56
9577282 1998
31
Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? 6
9443884 1998
32
The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. 6
9385372 1997
33
Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. 6
9215303 1997
34
Lipoprotein (a): its role in childhood thromboembolism. 56
9164807 1997
35
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 6
9011577 1997
36
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. 6
8647950 1996
37
Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. 56
8541836 1995
38
Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. 6
7623569 1995
39
Serum lipoprotein(a) levels in elderly black and white men in the Charleston Heart Study. 56
8313620 1993
40
Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. 6
8104271 1993
41
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. 6
7916578 1993
42
The molecular basis of the human serum paraoxonase activity polymorphism. 6
8098250 1993
43
Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. 56
1386087 1992
44
Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. 6
1311924 1992
45
Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. 56
2026424 1991
46
Inherited quantitative DNA variation in the LPA ("apolipoprotein (a)") gene. 56
1968792 1990
47
Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. 56
2556454 1989
48
The mysteries of lipoprotein(a). 56
2530631 1989
49
Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. 56
2976021 1988
50
Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. 56
2828221 1988
Sources

Variations for Lipoprotein Quantitative Trait Locus

About this section

ClinVar genetic disease variations for Lipoprotein Quantitative Trait Locus:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PON1 NM_000446.7(PON1):c.575A>G (p.Gln192Arg)SNV risk factor 13735 rs662 7:94937446-94937446 7:95308134-95308134
2 PON1 NM_000446.7(PON1):c.163T>A (p.Leu55Met)SNV risk factor 13736 rs854560 7:94946084-94946084 7:95316772-95316772
3 IRS1 NM_005544.2(IRS1):c.2911G>A (p.Gly971Arg)SNV risk factor 29761 rs1801278 2:227660544-227660544 2:226795828-226795828
4 TERT TERT, -1327T-CSNV Uncertain significance 12734

Copy number variations for Lipoprotein Quantitative Trait Locus from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13312 1 1 117600000 Copy number Coronary Disease
2 207742 6 160872504 161007397 Copy number LPA Coronary Disease
3 207743 6 160872504 161007397 Copy number LPA Coronary Disease
4 250037 9 19900000 32800000 Copy number Coronary Disease
Sources

Expression for Lipoprotein Quantitative Trait Locus

About this section
Search GEO for disease gene expression data for Lipoprotein Quantitative Trait Locus.
Sources

Pathways for Lipoprotein Quantitative Trait Locus

About this section

Pathways related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Folate Metabolism 1
Show member pathways
 11.96 PLG CRP APOB ALB
2
cGMP-PKG signaling pathway 36
Show member pathways
 11.93 TNNT2 TNNI3 NPPB NOS3 KNG1 IRS1
3
Dilated cardiomyopathy (DCM) 36
Show member pathways
 11.73 TNNT2 TNNI3 EDN1 ACE
4
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11.45 NOS3 KNG1 ACE
5
amb2 Integrin signaling 1
10.61 PLG LPA KNG1 APOB
6
Effects of Nitric Oxide 1
10.16 NOS3 MB
Sources

GO Terms for Lipoprotein Quantitative Trait Locus

About this section

Cellular components related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 PON1 PLG NPPB LPA KNG1 IL1RN
2 blood microparticle GO:0072562 9.56 PON1 PLG KNG1 ALB
3 platelet alpha granule lumen GO:0031093 9.54 PLG KNG1 ALB
4 troponin complex GO:0005861 9.4 TNNT2 TNNI3
5 extracellular space GO:0005615 9.4 PON1 PLG NPPB MIR223 MIR150 KNG1
6 cardiac myofibril GO:0097512 9.32 TNNT2 TNNI3
7 cardiac Troponin complex GO:1990584 9.16 TNNT2 TNNI3

Biological processes related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.62 PLG KNG1 APOB ALB
2 positive regulation of renal sodium excretion GO:0035815 9.48 NPPB EDN1
3 positive regulation of urine volume GO:0035810 9.46 NPPB EDN1
4 low-density lipoprotein particle remodeling GO:0034374 9.43 LPA APOB
5 negative regulation of blood coagulation GO:0030195 9.4 KNG1 EDN1
6 negative regulation of ATPase activity GO:0032780 9.37 TNNT2 TNNI3
7 body fluid secretion GO:0007589 9.26 NPPB EDN1
8 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.16 NOS3 EDN1
9 regulation of blood vessel diameter GO:0097746 9.13 NPPB NOS3 ACE
10 regulation of blood pressure GO:0008217 8.92 NPPB NOS3 EDN1 ACE

Molecular functions related to Lipoprotein Quantitative Trait Locus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 troponin C binding GO:0030172 8.62 TNNT2 TNNI3
Sources

Sources for Lipoprotein Quantitative Trait Locus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....